UPDATE 2-Amgen's postmenopausal osteoporosis drug wins FDA panel backing
January 16, 2019 at 17:56 PM EST
An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval.